In this issue:
- 3-year follow-up of mosunetuzumab in relapsed/refractory follicular lymphoma
- Glofitamab-gemcitabine oxaliplatin for relapsed/ refractory DLBCL
- Frontline asciminib monotherapy in chronic phase CML
- Anti-CD30 CAR T-cells in relapsed/refractory classical Hodgkin lymphoma
- RT omission in primary mediastinal B-cell lymphoma
- Adding isatuximab to VRd for MM
- Daratumumab vs. active monitoring for high-risk smouldering MM
- Real-life standards of care in triple-class-exposed, relapsed/refractory MM
- Talquetamab-teclistamab in relapsed/refractory MM
- Impact of dexamethasone dose intensity in newly diagnosed MM
Please login below to download this issue (PDF)